Search results
Showing 151 to 165 of 1505 results for patients and public
This guide describes the process NICE uses to develop indicators from NICE quality standards, NICE guidance and NICE accredited sources
In development Reference number: GID-TA11279 Expected publication date: 21 January 2026
Biographies and registered interests for members of the Technology Appraisal Committee C
In development Reference number: GID-TA11023 Expected publication date: TBC
Neuroendocrine tumours (metastatic, unresectable, progressive) - everolimus and sunitinib [ID858]
In development Reference number: GID-TA10024 Expected publication date: 28 June 2017
Integrated health and social care for people experiencing homelessness (NG214)
This guideline covers providing integrated health and social care services for people experiencing homelessness. It aims to improve access to and engagement with health and social care, and ensure care is coordinated across different services.
Read biographies of the members of our quality standards advisory committee.
Cannabidiol with clobazam for treating seizures associated with Lennox–Gastaut syndrome (TA615)
Evidence-based recommendations on cannabidiol (Epidyolex) with clobazam for seizures associated with Lennox–Gastaut syndrome in people aged 2 years and older.
Find out more about the NICE technology appraisal advisory committee B members and their registered interests
Aquablation robotic therapy for lower urinary tract symptoms caused by benign prostatic hyperplasia
Awaiting development Reference number: GID-MT599 Expected publication date: TBC
This guideline covers the general principles for managing intravenous (IV) fluid therapy in hospital inpatients aged 16 and over with a range of conditions. It aims to help prescribers understand the optimal amount and composition of IV fluids to be administered and the best rate at which to give them, to improve fluid prescribing and outcomes among people in hospital. It does not cover pregnant women, and those with severe liver or renal disease, diabetes or burns.
In development Reference number: GID-TA11519 Expected publication date: 12 June 2026
Dupilumab for treating severe chronic rhinosinusitis with nasal polyps (review of TA648) [ID6480]
In development Reference number: GID-TA11630 Expected publication date: TBC
Complicated intra-abdominal infections: ceftolozane/tazobactam (ESNM75)
Summary of the evidence on ceftolozane/tazobactam for treating complicated intra-abdominal infections to inform local NHS planning and decision-making
In development Reference number: GID-HTE10069 Expected publication date: 11 August 2026